These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 1973944

  • 21. Treating the anxiety: therapeutic options in obsessive compulsive disorder.
    Greist JH.
    J Clin Psychiatry; 1990 Nov; 51 Suppl():29-34. PubMed ID: 2146255
    [Abstract] [Full Text] [Related]

  • 22. Clomipramine use in obsessive-compulsive disorder.
    Ivey JL, Rosenberg DR.
    Expert Rev Neurother; 2002 Nov; 2(6):783-90. PubMed ID: 19810911
    [Abstract] [Full Text] [Related]

  • 23. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL.
    J Clin Psychopharmacol; 1992 Feb; 12(1):11-8. PubMed ID: 1552034
    [Abstract] [Full Text] [Related]

  • 24. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA, Seay SM.
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [Abstract] [Full Text] [Related]

  • 25. [Psychobiology of compulsive disease].
    Lesch KP.
    Fortschr Neurol Psychiatr; 1991 Oct; 59(10):404-12. PubMed ID: 1761269
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment.
    Kawahara T, Ueda Y, Mitsuyama Y.
    Psychiatry Clin Neurosci; 2000 Oct; 54(5):599-601. PubMed ID: 11043813
    [Abstract] [Full Text] [Related]

  • 29. Buspirone in obsessive-compulsive disorder.
    Maruno CA, Hart LL.
    Ann Pharmacother; 1992 Oct; 26(10):1248-51. PubMed ID: 1421651
    [No Abstract] [Full Text] [Related]

  • 30. Intravenous anti-obsessive agents: a review.
    Ravindran LN, Jung SM, Ravindran AV.
    J Psychopharmacol; 2010 Mar; 24(3):287-96. PubMed ID: 18801828
    [Abstract] [Full Text] [Related]

  • 31. Serotonin and effect sizes of antiobsessive agents.
    Pato MT, Gluhoski V.
    Am J Psychiatry; 1992 Mar; 149(3):420-1. PubMed ID: 1531582
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL, McDougle CJ, Epperson CN, Price LH.
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [Abstract] [Full Text] [Related]

  • 37. Azapirones: history of development.
    Eison AS.
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):2S-5S. PubMed ID: 1973936
    [Abstract] [Full Text] [Related]

  • 38. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
    Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R.
    Am J Psychiatry; 1990 Jul; 147(7):923-8. PubMed ID: 2192564
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
    Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL.
    Am J Psychiatry; 1993 May; 150(5):819-21. PubMed ID: 8480832
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.